Psychedelics: A New Treatment Paradigm in Psychiatry?

The renaissance of psychedelics has accelerated further over the past year. At least that’s true if you follow the public press. The New York Times recently titled “The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same.” on its front page [1].

Publikationsverlauf

Eingereicht: 25. Mai 2021
Eingereicht: 25. Mai 2021

Angenommen: 26. Mai 2021

Artikel online veröffentlicht:
24. Juni 2021

• References

• 1 The New York Times. The psychedelic revolution is coming. Psychiatry may never be the same. 2021; https://www.nytimes.com/2021/05/09/health/psychedelics-mdma-psilocybin-molly-mental-health.html (accessed on May 21^st, 2021)
• 2 Mitchell JM, Bogenschutz M, Lilienstein A. et al. MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021 DOI: 10.1038/s41591-021-01336-3
• 3 Carhart-Harris R, Giribaldi B, Watts R. et al. trial of psilocybin versus escitalopram for depression. N Engl J Med 2021; 384: 1402-1411
• 4 Yaden DB, Yaden ME, Griffiths RR. psychedelics in psychiatry-keeping the renaissance from going off the rails. J Am Med Assoc Psychiatry 2021; 78: 469-470
• 5 Nichols DE, Walter H. The history of psychedelics in psychiatry. Pharmacopsychiatry. 2021; 54: 151-166 DOI: 10.1055/a-1310-3990.
• 6 Nayak S, Johnson MW. Psychedelics and psychotherapy. Pharmacopsychiatry. 2021; 54: 167-175 DOI: 10.1055/a-1312-7297.
• 7 Mertens LJ, Preller KH. Classical psychedelics as therapeutics in psychiatry—current clinical evidence and potential therapeutic mechanisms in substance use and mood disorders. Pharmacopsychiatry. 2021; 54: 176-190 DOI: 10.1055/a-1341-1907.
• 8 Gründer G, Jungaberle H. The potential role of psychedelic drugs in mental health care of the future. Pharmacopsychiatry. 2021; 54: 191-199 DOI: 10.1055/a-1486-7386.